drugset
drugset / Trial / NCT01486823

Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

NCT01486823 ↗

Phase 1 Completed 22 enrolled BioInvent International AB Genentech, Inc. · collab
Non-randomizedParallel-groupOpen-label

Summary

This is a study in healthy volunteers designed to investigate the PK following intravenous and subcutaneous administration of MLDL1278A (also known as BI-204). The bioavalialbility of MLDL1278A after subcutaneous administration will be determined.

Timeline

Start
2011-11
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Orticumab Protein / enzyme biologic 360 mg Intravenous

Indications

No indication recorded.